Gsa Capital Partners LLP Erasca, Inc. Transaction History
Gsa Capital Partners LLP
- $1.32 Billion
- Q3 2024
A detailed history of Gsa Capital Partners LLP transactions in Erasca, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 60,848 shares of ERAS stock, worth $154,553. This represents 0.01% of its overall portfolio holdings.
Number of Shares
60,848
Previous 113,383
46.33%
Holding current value
$154,553
Previous $268,000
38.06%
% of portfolio
0.01%
Previous 0.02%
Shares
10 transactions
Others Institutions Holding ERAS
# of Institutions
140Shares Held
229MCall Options Held
28.7KPut Options Held
117K-
Frazier Life Sciences Management, L.P. Menlo Park, CA19.4MShares$49.3 Million2.85% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD16.8MShares$42.8 Million0.03% of portfolio
-
Vr Adviser, LLC New York, NY16.2MShares$41.2 Million4.58% of portfolio
-
Suvretta Capital Management, LLC New York, NY13.8MShares$35 Million1.48% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$33.8 Million0.0% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $310M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...